Dehydrocorydaline (hydroxyl)

• CAT Number: I041214
• Molecular Formula: C22H25NO5
• Molecular Weight: 383.44
• Purity: ≥95%
• Synonyms: 2,3,9,10-tetramethoxy-13-methyl-5,6-dihydroisoquinolino[2,1-b]isoquinolin-7-ium;hydroxide
• InChI: InChI=1S/C22H24NO4.H2O/c1-13-15-6-7-18(24-2)22(27-5)17(15)12-23-9-8-14-10-19(25-3)20(26-4)11-16(14)21(13)23;/h6-7,10-12H,8-9H2,1-5H3;1H2/q+1;/p-1
• InChIKey: VABDSZRJMKHGCS-UHFFFAOYSA-M
• SMILES: CC1=C2C=CC(=C(C2=C[N+]3=C1C4=CC(=C(C=C4CC3)OC)OC)OC)OC.[OH-]

Dehydrocorydaline (13-Methylpalmatine) hydroxyl is an alkaloid that regulates protein expression of Bax, Bcl-2; activates caspase-7, caspase-8, and inactivates PARP. Dehydrocorydaline hydroxyl elevates p38 MAPK activation. Anti-inflammatory and anti-cancer activities. Dehydrocorydaline hydroxyl shows strong anti-malarial effects (IC50=38 nM), and low cytotoxicity (cell viability > 90%) using P. falciparum 3D7 strain.
Dehydrocorydaline hydroxyl (0-200 μM) treatment significantly inhibits the growth of MCF-7 cells in a dose-dependent manner. The cell viability is decreased by approximate 40% after 24 h of 200 μM Dehydrocorydaline hydroxyl[1].
Dehydrocorydaline hydroxyl (0-200 μM)dose-dependently increases Bax protein expression and decreases Bcl-2 protein expression[1].
Dehydrocorydaline hydroxyl (0-200 μM)induces activation of caspase-7,-8 and the cleavage of PARP without affecting caspase-9[1].
Dehydrocorydaline hydroxyl manifests a low acute toxicity with an LD50 of about 277.5±19.0 mg/kg body weight in mice following oral administration and 21.1±1.4 mg/kg for intraperitoneal injection[4].

Reference

[1]. Xu Z, et al. Dehydrocorydaline inhibits breast cancer cells proliferation by inducing apoptosis in MCF-7 cells. Am J Chin Med. 2012;40(1):177-85.
 [Content Brief]

[2]. Yoo M, et al. Dehydrocorydaline promotes myogenic differentiation via p38 MAPK activation. Mol Med Rep. 2016 Oct;14(4):3029-36.
 [Content Brief]

[3]. Nonaka M, et al. Screening of a library of traditional Chinese medicines to identify anti-malarial compounds and extracts. Malar J. 2018 Jun 25;17(1):244.
 [Content Brief]

[4]. Yin ZY, et al. Antinociceptive effects of dehydrocorydaline in mouse models of inflammatory pain involve the opioid receptor and inflammatory cytokines. Sci Rep. 2016 Jun 7;6:27129.
 [Content Brief]